Tivic Health Systems (TIVC) Maxim Group’s 2024 Healthcare Virtual Summit summary

Conference overview

• Fifth annual virtual healthcare conference featuring over 85 company presentations, primarily by CEOs, spanning three days through October 17th.

• Tivic Health Systems presented by CEO Jennifer Ernst, focusing on bioelectronic medicine and company developments.

Company and technology highlights

• Operates in bioelectronic medicine, leveraging electrical signals in the body for therapeutic effects, with two main platforms: a marketed sinus treatment device and a developing vagus nerve stimulation (VNS) platform.

• The sinus device is FDA-approved, available through multiple channels, and addresses a $9.1 billion market opportunity.

• VNS platform targets the neck area non-invasively, showing strong clinical results comparable to or better than implanted devices.

• Collaborating with the Feinstein Institute to optimize VNS parameters and programming for various disease states.

Clinical and commercial progress

• VNS platform is in proof-of-concept stage, with phase II trials expected next year.

• Early clinical data show significant improvements in heart rate variability and brainwave activity.

• Strategic consultancy identified 10 strong VNS application candidates, narrowing to 2-3, with more details expected soon.

• Potential indications include cardiovascular, neurologic, stroke rehabilitation, and mental health applications.